PremiumRatingsCentessa Pharmaceuticals: Promising Potential in Neuropsychiatric Disorders with ORX750 and Orexin Agonist Pipeline Centessa Pharmaceuticals: Promising Orexin Pipeline and Strong Financials Drive Buy Rating Promising Potential of Centessa Pharmaceuticals’ Orexin Agonist Pipeline Drives Buy Rating PremiumRatingsCentessa Pharmaceuticals: A Compelling Buy with Promising Orexin Portfolio and Significant Upside Potential Centessa assumed with an Overweight at Morgan Stanley Centessa Pharmaceuticals Updates on OX2R Agonist Pipeline PremiumThe FlyCentessa management to meet with Oppenheimer Centessa price target raised to $28 from $24 at Guggenheim Alkermes price target raised to $31 from $28 at BofA 
